Microbiome company Seres raises $48M

Seres Health Inc. (Cambridge, Mass.) raised $48 million in a series C round with undisclosed public investors. Neither Seres nor founding investor Flagship Ventures would tell BioCentury who any of the investors in the round were, nor confirm whether prior investors participated.

Next year, Seres expects to begin a Phase III study of SER-109 to prevent recurrence of Clostridium difficile infections. The compound is an orally available mixture of undisclosed bacteria. Seres would not say when it expects data from the trial, nor discuss development timelines for any of its other compounds. ...